Giunta Alessandro, Babino Graziella, Ruzzetti Manuela, Manetta Sara, Chimenti Sergio, Esposito Maria
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
J Int Med Res. 2016 Sep;44(1 suppl):72-75. doi: 10.1177/0300060515593254.
To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis.
Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80 kg or ≥80 kg) and BMI (healthy, BMI 22 - 24.99 kg/m; overweight, BMI 25 - 29.99 kg/m; obese, BMI ≥30 kg/m).
The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n = 12) compared with healthy weight (n = 33) or overweight (n = 21) patients.
Obesity has a negative effect on the efficacy of etanercept in psoriasis.
探讨体重指数（BMI）和体重在银屑病患者中使用依那西普长期疗效的作用。
对病历进行回顾性分析。提取的数据包括体重、BMI、合并症和银屑病面积严重程度指数（PASI）。患者按体重（<80 kg或≥80 kg）和BMI（健康，BMI 22 - 24.99 kg/m²；超重，BMI 25 - 29.99 kg/m²；肥胖，BMI≥30 kg/m²）进行分层。
该研究纳入66例患者。体重对依那西普疗效无影响。与健康体重（n = 33）或超重（n = 21）患者相比，肥胖患者（n = 12）使用依那西普的疗效显著降低。
肥胖对依那西普治疗银屑病的疗效有负面影响。
